Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elizabeth Orr

Washington, DC
Elizabeth Orr focuses on legal affairs affecting the medical device industry. Before joining Informa in September 2015, she spent three years spent reporting on all things device-related at FDANews. She remains fascinated by the ever-changing master class on technology, government regulations, advances in health care and more that is covering the device industry. Elizabeth’s past employers include DecisionHealth (formerly UCG); the Society of Interventional Radiology; and the Washington Examiner.  A graduate of the College of Journalism at the University of Maryland College Park, she lives in Arlington, Va., with her husband and children.

Latest From Elizabeth Orr

FDA, NIST Join Forces To Improve Manufacturing, Quell Device Shortages

The focus on innovative manufacturing will also include a new clearinghouse to share info about advanced manufacturing technology within the US agency’s device center.

FDA Innovation

Government Report Outlines Costs, Savings Of Major Regs

The US HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.

Regulation Government Payers

US FDA Panel To Take Up Lutonix DCB Catheter For Lower-Leg Use Next Month

If approved, the device will be the first drug-coated balloon indicated specifically for use in arteries below the knee.

Advisory Committees Regulation

Device Week, 14 January 2021 – FDA Commissioner News; Spotlight On COVID-19 Enforcement Issues

On this week’s podcast we talk about outgoing US FDA chief Stephen Hahn and the role he wants to play beyond 20 January, as an ex-commissioner. We also discuss the US enforcement landscape around COVID-19-related products and how it’s still taking shape.

FDA Leadership

Attorneys Expect COVID-19 ‘Enforcement Press’ Centered On PREP Act, Diagnostics

Three attorneys got out their crystal balls to forecast what device industry sectors may come in for enforcement scrutiny related to the COVID-19 pandemic.

Enforcement FDA

With Sun Setting On Trump Admin, HHS Finalizes Regulatory Review Rule

In a change from the draft, the final rule exempts device-specific regulations from scheduled review.

Regulation Policy
See All
UsernamePublicRestriction

Register